ClinicalTrials.gg
CompletedNCT02693106Updated Mar 25, 2020Results posted

Evaluation of the Ketogenic Potential of Different Diet Supplements

An interventional study of Control and Leucine in Healthy Adults, sponsored by Université de Sherbrooke. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate the capacity of different dietary supplements to increase ketone production in healthy adults.

Read the detailed description

The aim of this study is to evaluate the capacity of different dietary supplements to increase ketone production in healthy adults. Each supplement (leucine, butyrate, octanoate, carnitine or butter fraction rich in MCT) is evaluated for a period of 4-hour during which multiple blood samples are taken in order to measure ketone production.

02

Conditions studied

  • Healthy Adults

Browse trials for

Keywords

  • Ketones
  • Butyrate
  • Leucine
  • Octanoate
  • Carnitine
  • Medium Chain Triglycerides
03

In context

Ketosis

195 studies on the registry are indexed under Ketosis; 41 are open to participants now.

This study's enrollment of 13 is below the median of 24 across 156 interventional studies indexed under Ketosis.

Browse Ketosis studies →

Lead sponsor

Université de Sherbrooke is the lead sponsor of 296 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged of 18 years old or older.
  • Non-smoking.

Exclusion criteria

Exclusion Criteria:

  • Diabetes or prediabetes
  • Uncontrolled hypertension
  • Uncontrolled thyroid function
  • Taking medication that will affect lipid/glucose metabolism
  • Severe infection or inflammation
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Ketogenic potential

    Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling. Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT

    Dietary Supplement: Control · Dietary Supplement: Leucine · Dietary Supplement: Butyrate - · Dietary Supplement: Butyrate + · Dietary Supplement: Octanoate - · Dietary Supplement: Octanoate + · Dietary Supplement: Carnitine · Dietary Supplement: Butter fraction

Interventions

  • Dietary supplementControl

    Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.

    Also known as: CTL

  • Dietary supplementLeucine

    Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementButyrate -

    Drug pages: Butyrates · Butyric Acid

    Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementButyrate +

    Drug pages: Butyrates · Butyric Acid

    Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementOctanoate -

    Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementOctanoate +

    Drug page: Octanoic acid

    Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementCarnitine

    Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.

  • Dietary supplementButter fraction

    Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.

06

What researchers measure

Primary outcomes

  1. Concentration of Total Plasma Ketones

    Difference from Time 0 in Total ketones = acetoacetate (umol/L) + beta-hydroxybutyrate (umol/L) Time 0 is when the participants arrived, after a 12 hours fast, i.e. before the breakfast. Plasma was collected every 30 minutes for 4 hours immediately following breakfast (where supplements were taken). Results are the mean of plasma ketones measured every 30 minutes ( i.e. total of 9 plasma samples) for the 4 hour period. For each time point, the difference form time 0 has been made. So this is the mean of the difference from time 0 in total ketones. Data were not collected for the 'Intervention 8: 65 g of butter fraction rich in MCT' supplement.

    Time frame: 4 hours

07

Results

Posted Mar 25, 2020

Participant flow

Participant flow — Overall Study
MilestoneKetogenic Potential
Started13
Completed10
Not completed3
Withdrew: No time3

Outcome measures

PrimaryConcentration of Total Plasma Ketones

Difference from Time 0 in Total ketones = acetoacetate (umol/L) + beta-hydroxybutyrate (umol/L) Time 0 is when the participants arrived, after a 12 hours fast, i.e. before the breakfast. Plasma was collected every 30 minutes for 4 hours immediately following breakfast (where supplements were taken). Results are the mean of plasma ketones measured every 30 minutes ( i.e. total of 9 plasma samples) for the 4 hour period. For each time point, the difference form time 0 has been made. So this is the mean of the difference from time 0 in total ketones. Data were not collected for the 'Intervention 8: 65 g of butter fraction rich in MCT' supplement.

Time frame:
4 hours
Reported as:
Mean · µmol/L
Concentration of Total Plasma Ketones
µmol/LKetogenic Potential
CTL-18.2 ± 20
Leucine23 ± 25
Butyrate 3.6g12.2 ± 44.4
Butyrate 7.2g68.5 ± 35.9
Octanoate 5g-3.4 ± 32.8
Octanoate 10 g39.7 ± 34
Carnitine-30 ± 21.4

Adverse events

Collected over 8 visits of 4 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control, no Supplement—0/10 (0%)0/10 (0%)
5g of Leucine—0/10 (0%)0/10 (0%)
3.6g de Butyrate—0/10 (0%)2/10 (20%)
7.2g de Butyrate—0/10 (0%)3/10 (30%)
5g d'Octanoate—0/10 (0%)2/10 (20%)
10g d'Octanoate—0/10 (0%)3/10 (30%)
1.95g de Carnitine—0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
EventControl, no Supplement5g of Leucine3.6g de Butyrate7.2g de Butyrate5g d'Octanoate10g d'Octanoate1.95g de Carnitine
HeadacheGeneral disorders0/100/100/103/100/100/100/10
gastric refluxGastrointestinal disorders0/100/100/100/102/103/100/10
DiarrheaGastrointestinal disorders0/100/102/102/100/100/100/10
NauseaGeneral disorders0/100/100/102/100/102/100/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ketogenic Potential
<=18 years0
Between 18 and 65 years13
>=65 years0
Age, Continuous
Age, Continuous(years)Ketogenic Potential
Mean34 ± 4
Sex: Female, Male
Sex: Female, Male(Participants)Ketogenic Potential
Female10
Male3
Region of Enrollment
Region of Enrollment(Participants)Ketogenic Potential
Canada13
08

Study locations

1 site
  • Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)
    Sherbrooke, Quebec J1H4C4, Canada
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02693106
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
Jul 2013
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Mar 25, 2020
Last update
Mar 25, 2020

Study contacts

Stephen Cunnane, PhD
principal investigator · Research Centre on Aging CSSS-IUGS - CIUSSS de l'Estrie - CHUS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leucine · Butyrates · Butyric Acid · Octanoic acid · Carnitine

Start the discussion